Scotiabank Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive. But ...
GEN - Genetic Engineering and Biotechnology News5h
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Notable healthcare headlines for the week: Pfizer, Sanofi, Sarepta Therapeutics and Medtronic in focus
Discover the top gainers and losers in the S&P 500 Healthcare Index and stay updated on major news like J&J's $55B investment and Pfizer's Haleon stake exit.
Wall Street Week Ahead
Stay updated with Wall Street's weekly highlights: key inflation data, CoreWeave IPO, and earnings reports. Insights on ...